- ISIN
- US89357L1052
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Jul 8, 2021
Highlights
- Market Cap
- $4.83M
- Enterprise Value
- -$17.81B
- EPS (TTM)
- -$32.55
- Gross Profit (TTM)
- -$69.40K
- EBITDA (TTM)
- -$26.93M
- Year Range
- $3.82 - $20.99
- ROA (TTM)
- -0.02%
- ROE (TTM)
- -0.26%
- Avg. Volume (1M)
- 26K
- Avg. Volume Value (1M)
- $196.69K
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
RNAZ Performance Chart
Transcode Therapeutics Inc (RNAZ) is down 33.2% since the beginning of the year. At $5 per share, RNAZ is trading 78.3% below its 52-week high of $21. Investors who bought $1,000 worth of RNAZ shares 5 years ago would now be looking at an investment worth $0.
Loading charts...
Compare this symbol against anything
Returns By Period
Transcode Therapeutics Inc (RNAZ) has returned -33.24% so far this year and -60.35% over the past 12 months.
Transcode Therapeutics Inc
- 1D
- -13.14%
- 1M
- -47.04%
- 6M
- -51.95%
- YTD
- -33.24%
- 1Y
- -60.35%
- 3Y*
- -96.11%
- 5Y*
- -92.67%
- 10Y*
- —
- ALL TIME*
- -92.89%
Benchmark (S&P 500 Index)
- 1D
- 0.70%
- 1M
- 0.09%
- 6M
- 7.94%
- YTD
- 9.41%
- 1Y
- 20.07%
- 3Y*
- 17.84%
- 5Y*
- 11.25%
- 10Y*
- 13.26%
- ALL TIME*
- 8.09%
RNAZ Monthly Returns History
Based on dividend-adjusted daily data since Jul 8, 2021, RNAZ's average daily return is -0.39%, while the average monthly return is -9.24%.
Historically, 26% of months were positive and 74% were negative. The best month was May 2024 with a return of +192.4%, while the worst month was Jan 2024 at -89.5%. The longest winning streak lasted 2 consecutive months, and the longest losing streak was 12 months.
On a daily basis, RNAZ closed higher 42% of trading days. The best single day was Sep 25, 2023 with a return of +284.0%, while the worst single day was Sep 26, 2023 at -72.9%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 38.95% | 1.26% | -10.41% | -6.97% | -35.83% | 20.82% | -26.57% | -33.24% | |||||
| 2025 | 124.33% | -73.81% | -75.00% | -17.86% | -40.36% | 14.87% | 42.31% | -12.34% | 10.48% | 4.19% | -17.05% | -26.48% | -92.76% |
| 2024 | -89.52% | 1.97% | -3.07% | -11.11% | 192.37% | -43.38% | -72.14% | -5.93% | 116.78% | -18.56% | -25.16% | -70.65% | -98.45% |
| 2023 | 11.56% | -30.61% | -35.03% | -6.68% | -33.52% | -45.24% | -4.35% | -34.09% | -65.33% | -26.36% | -33.55% | -33.01% | -98.78% |
| 2022 | -9.45% | -7.39% | 35.21% | -5.21% | -32.60% | -31.52% | 12.70% | -15.49% | -8.33% | -38.91% | -40.48% | 68.25% | -73.50% |
| 2021 | -27.25% | 4.47% | -1.64% | -5.35% | -2.83% | -7.64% | -36.50% |
Benchmark Metrics
Transcode Therapeutics Inc has an annualized alpha of -68.49%, beta of 1.30, and R2 of 0.01 versus S&P 500 Index. Calculated based on daily prices since July 08, 2021.
- This stock participated in 275.95% of S&P 500 Index downside but only -145.90% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.01 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -68.49%
- Beta
- 1.30
- R²
- 0.01
- Upside Capture
- -145.90%
- Downside Capture
- 275.95%
Return for Risk
Risk / Return Rank
RNAZ ranks 14 for risk / return — above 14% of stocks peers on PortfoliosLab. Its historical combined result is below most peers; review the five component ranks for context.
Risk / Return Metrics
The table below present risk-adjusted performance metrics for Transcode Therapeutics Inc (RNAZ) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| RNAZ | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -2.02 | ||
| Sortino ratioReturn per unit of downside risk | -2.67 | ||
| Omega ratioGain probability vs. loss probability | 0.93 | 1.25 | -0.33 |
| Calmar ratioReturn relative to maximum drawdown | -0.84 | 2.00 | -2.85 |
| Martin ratioReturn relative to average drawdown | -1.42 | 8.49 | -9.92 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Transcode Therapeutics Inc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Transcode Therapeutics Inc was 100.00%, occurring on Jun 25, 2026. The portfolio has not yet recovered.
The current Transcode Therapeutics Inc drawdown is 100.00%.
Drawdown | Fall | Recovery | Underwater | Related event |
|---|---|---|---|---|
-100.00%Jun 2026 | 4y 11mo | — | 5y 22dJul 2021 - now | — |
Drawdown Indicators
| RNAZ | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -100.00% | -56.78% | -43.22% |
Max Drawdown (1Y)Largest decline over 1 year | -70.12% | -9.10% | -61.02% |
Max Drawdown (3Y)Largest decline over 3 years | -100.00% | -18.90% | -81.10% |
Max Drawdown (5Y)Largest decline over 5 years | -100.00% | -25.43% | -74.57% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -100.00% | -1.58% | -98.42% |
Average DrawdownAverage peak-to-trough decline | -89.84% | -10.70% | -79.14% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 41.41% | 2.14% | +39.27% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Transcode Therapeutics Inc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Transcode Therapeutics Inc is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
Income Statement
| TTM | |
|---|---|
Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with RNAZ
Add Transcode Therapeutics Inc to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with RNAZ